Yonny Appratto
Family · Winter Haven, FLNPI 1275169518
Payments from drug & device makers
Across 584 payments — averaging $17.15 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$1K
- Bayer$974
- Amgen$776
- Dexcom, Inc.$768
- Novo Nordisk$651
- Merck$608
- plus $5K from 30 others
What the payments were for
- Food & beverage$10,013100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 70 | $1,202 |
| Bayer | 70 | $974 |
| Amgen | 59 | $776 |
| Dexcom, Inc. | 46 | $768 |
| Novo Nordisk | 43 | $651 |
| Merck | 35 | $608 |
| Pfizer | 30 | $547 |
| Boehringer Ingelheim | 21 | $441 |
| AbbVie | 21 | $413 |
| Daiichi Sankyo Inc. | 20 | $354 |
| Novartis | 19 | $353 |
| Exact Sciences | 13 | $335 |
| Esperion Therapeutics, Inc. | 17 | $299 |
| Lilly USA, LLC | 15 | $290 |
| Johnson & Johnson | 16 | $286 |
| Astellas Pharma US Inc | 11 | $274 |
| E.r. Squibb & Sons, L.L.C. | 14 | $251 |
| GSK | 11 | $201 |
| Amarin Pharma, Inc. | 9 | $175 |
| Biohaven Pharmaceutical Holding Company Ltd. | 8 | $126 |
| Sumitomo Pharma America, Inc. | 6 | $104 |
| Boston Scientific | 4 | $92 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 4 | $79 |
| Paratek Pharmaceuticals, Inc. | 3 | $66 |
| Biohaven Pharmaceuticals, Inc. | 3 | $57 |
| Lifescan, Inc. | 2 | $49 |
| Averitas Pharma Inc. | 2 | $45 |
| Sunovion Pharmaceuticals Inc. | 3 | $44 |
| Abbott | 1 | $25 |
| Kowa Pharmaceuticals America, Inc. | 2 | $24 |
| Medtronic | 1 | $20 |
| Vanda Pharmaceuticals Inc. | 1 | $19 |
| Axsome Therapeutics, Inc. | 1 | $18 |
| Sanofi-aventis U.S. LLC | 1 | $16 |
| Inogen, Inc. | 1 | $15 |
| Idorsia Pharmaceuticals US Inc | 1 | $13 |
How this compares
$10,013 in reported general payments places this provider in the 95th percentile of 14,618 family providers in Florida.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| FarxigaDapagliflozin Propanediol | 47 | $60,423 |
| OzempicSemaglutide | 20 | $38,727 |
| JardianceEmpagliflozin | 24 | $32,154 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 23 | $22,966 |
| TrulicityDulaglutide | 15 | $21,550 |
| EliquisApixaban | 18 | $20,658 |
| BelsomraSuvorexant | 16 | $6,861 |
| Atorvastatin Calcium | 251 | $2,055 |
| Levothyroxine Sodium | 107 | $1,346 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 41 | $1,208 |
| Gabapentin | 95 | $1,114 |
| Rosuvastatin Calcium | 115 | $1,077 |
| Diltiazem 24hr Er (La)Diltiazem Hcl | 11 | $959 |
| Metoprolol Succinate | 42 | $958 |
| Tamsulosin Hcl | 75 | $904 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaFarxiga | $1,202 | $60,42347 claims |
| Novo NordiskOzempic | $651 | $38,72720 claims |
| Boehringer IngelheimJardiance | $441 | $32,15424 claims |
| GSKTrelegy Ellipta | $201 | $22,96623 claims |
| Lilly USA, LLCTrulicity | $290 | $21,55015 claims |
| PfizerEliquis | $547 | $20,65818 claims |
| MerckBelsomra | $608 | $6,86116 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 14,618 family providers in Florida.
Other family in Winter Haven
- John HuffakerVenice$8M
- Stephanie MompointMiami$4.5M
- Miguel TrujilloMiami Gardens$4.4M
- Itsel Cardenas RamonMiami$1M
- Lewis HarringtonTampa$954K
- Adam StrosbergFort Lauderdale$859K
- Danielle PharesFt Lauderdale$713K
- David RodriguezHialeah$658K
- Donna OrtizOrlando$417K
- Patrick SzarazMiami$327K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.